Liver cancer is an aggressive disease with a poor outcome. Several hepatic stem/progenitor markers are useful for isolating a subset of liver cells with stem cell features, known as cancer stem cells (CSCs). These cells are responsible for tumor relapse, metastasis, and chemoresistance. Liver CSCs dictate a hierarchical organization that is shared in both organogenesis and tumorigenesis. An increased understanding of the molecular signaling events that regulate cellular hierarchy and stemness, and success in defining key CSC-specific genes, have opened up new avenues to accelerate the development of novel diagnostic and treatment strategies. This Review highlights recent advances in understanding the pathogenesis of liver CSCs and discusses unanswered questions about the concept of liver CSCs.

Find the latest version:

http://jci.me/66024-pdf
Liver cancer is an aggressive disease with a poor outcome. Several hepatic stem/progenitor markers are useful for isolating a subset of liver cells with stem cell features, known as cancer stem cells (CSCs). These cells are responsible for tumor relapse, metastasis, and chemoresistance. Liver CSCs dictate a hierarchical organization that is shared in both organogenesis and tumorigenesis. An increased understanding of the molecular signaling events that regulate cellular hierarchy and stemness, and success in defining key CSC-specific genes, have opened up new avenues to accelerate the development of novel diagnostic and treatment strategies. This Review highlights recent advances in understanding the pathogenesis of liver CSCs and discusses unanswered questions about the concept of liver CSCs.

The cancer stem cell concept
Although considered monoclonal in origin, tumor cells show heterogeneous morphology and behavior (1, 2). This heterogeneity has traditionally been explained by the clonal evolution of tumor cells resulting from the progressive accumulation of multiple genetic (3) or epigenetic changes (4). Alterations in tumor stroma microenvironments may also facilitate the development of tumor cell heterogeneity through the extrinsic activation of certain tumor cell signaling pathways (5). Moreover, recent studies have suggested that heterogeneity is a result of the hierarchical organization of tumor cells by a subset of cells with stem/progenitor cell features known as cancer stem cells (CSCs) (6).

The concept of cancer as an abnormal stem cell disease was proposed based on the similar capabilities of cancer cells and normal stem cells to self-renew, produce heterogeneous progeny, and divide in an unlimited fashion (7, 8). However, the CSC hypothesis has only recently been experimentally validated by the identification of a subset of certain self-renewing stem cell marker–positive cells with a hierarchical organization (9–11). The self-renewal capacity is confirmed by serial in vitro clonogenic growth and in vivo tumorigenicity; thus, CSCs are also known as tumor-initiating cells or tumor-propagating cells. CSCs are highly tumorigenic, metastatic, chemotherapy and radiation resistant, responsible for tumor relapse after therapy, and able to divide symmetrically and asymmetrically to orchestrate the tumor mass (11). Therefore, CSCs are a pivotal target for the eradication of many cancers including liver cancer.

Liver cancer is the fifth most commonly diagnosed cancer and the second most frequent cause of cancer death in men worldwide (12). Among primary liver cancers, hepatocellular carcinoma (HCC) represents the major histological subtype, accounting for 70%–85% of cases of primary liver cancer (12). Intrahepatic cholangiocarcinoma (ICC) is the second most frequent type of liver cancer, and its incidence has been increasing (12, 13). Both HCC and ICC are heterogeneous diseases in terms of cellular morphology and clinical outcome. Combined HCC–cholangiocellular carcinoma (HCC-CCA), a form of primary liver cancer showing features of both hepatocellular and biliary epithelial differentiation, has also been reported, supporting the existence of bipotent liver CSCs (14). Indeed, recent immunohistochemical studies of stem cell markers suggest that HCC, ICC, and HCC-CCA are histologically heterogeneous and contain a subset of cells expressing a variety of stem cell markers (15–18).

CSC self-renewal and hierarchical organization features have been experimentally validated by xenotransplantation of freshly resected HCC specimens. In HCC, CSC markers include epithelial cell adhesion molecule (EpCAM), CD133, CD90, CD44, CD24, CD13, and oval cell marker OV6, as well as Hoechst dye efflux or aldehyde dehydrogenase activities, some of which may functionally support liver CSC phenotypes including highly invasive features and chemoresistance (18–24). This Review summarizes the current knowledge of liver CSCs and discusses several unanswered questions about the concept of liver CSCs.

Liver microenvironment and the CSC niche
Liver cancer nearly always develops in the setting of chronic liver disease (CLD), in which continuous inflammation and hepatocyte regeneration occur (25). Pathophysiological changes take place during long-term inflammation/regeneration processes that work coordinately to initiate and/or promote liver cancer. These processes include the expansion of stem/progenitor cells, accumulation of genetic and/or epigenetic changes, and alteration of the microenvironment (Figure 1).

Hepatic stem/progenitor cells are markedly elevated in CLDs (26). Under selected circumstances, the hepatocyte proliferative capacity is considered virtually infinite (27). However, in human CLDs, this capacity is impaired, possibly due to hepatitis virus infection (28) or replicative senescence induced by long-term continuous hepatocyte regeneration (29). This impairment in hepatocyte proliferation may cause the expansion of stem/progenitor cells called “ductular reactions” (30). Hepatic stem/progenitor cells derive from the canals of Hering, bile canaliculi lined with hepatocytes and cholangiocytes (31). Stem cell homing, motility, and proliferation are tightly regulated by the immediate microenvironment termed the stem cell niche (32). In the liver, the niche cells that control self-renewal and division of hepatic stem/progenitors have not yet been clarified. The magnitude of progenitor cell activation seems to correspond to the severity of liver fibrosis and inflammation (30) and correlate with HCC risk (33).
Genetic and epigenetic changes accumulate in all liver lineages over decades and are responsible for initiating and promoting liver cancer. HBV infection results in HBV genome integration into the host genome and may initiate and promote HCC by inducing insertional mutagenesis and genomic instability (34). The HBV X gene (HBx) also modulates signaling pathways, including p53 and NF-kB, to promote HCC (35). HCV infection may enhance the induction of ROS by modulating mitochondrial functions, resulting in DNA damage (36). Telomere shortening as a consequence of accelerated hepatocyte turnover also contributes to genomic instability and HCC (37). TP53 mutations, especially codon 249Ser mutations following aflatoxin B1 exposure, result in defective DNA damage responses (38). These oncogenic events may occur simultaneously in various populations of hepatic stem/progenitor cells and hepatocytes in CLDs.

The hepatic microenvironment is drastically altered in CLDs, with increased lymphocyte infiltration, stellate cell activation, and the expansion of hepatic progenitor cells and endothelial progenitor cells. Infiltrating lymphocytes cause inflammation with the release of free radicals, cytokines, and chemokines, resulting in DNA damage, cell proliferation, and migration (38, 39). Activation of stellate cells by TGF-β, possibly secreted from infiltrating lymphocytes, Kupffer cells, or damaged hepatocytes, results in fibrosis with excess deposition of extracellular matrix (40). Activated myofibroblasts in turn produce growth factors such as Wnt, FGF, and PDGF to regulate cell proliferation (41, 42). Endothelial progenitor cells and sinusoidal endothelial cells may migrate, proliferate, and subsequently mediate vasculature reconstruction during liver regeneration in part through interaction of VEGF and its receptor VEGFR (43, 44).

Taken together, stromal cell activation appears to induce signaling pathways in a range of liver lineages that emerge in CLDs with accumulating genetic and/or epigenetic changes. These patho-

Figure 1
Liver inflammation and regeneration in liver CSC development. Stem/progenitor cells expand in CLD as a result of impaired hepatocyte replication, and genetic and epigenetic changes potentially accumulate in all liver lineages. Activation of stromal cells may induce various signaling pathways, including cytokines such as Wnt, FGF, PDGF, VEGF, and TGF-β, and promote the development of liver CSCs.
physiological conditions may cooperatively affect the process of liver regeneration and may support liver CSC development.

Shared features of liver development and liver cancer development

Embryogenesis and tumorigenesis share similar features, including autonomous cell proliferation, motility, homing, dynamic morphologic changes, cellular heterogeneity, and interactions with the microenvironment. Indeed, carcinogenesis could be described as deregulated malignant organogenesis mediated by abnormally proliferating and/or metastatic cancer cells and activated stromal cells that trigger angiogenesis, fibrosis, and inflammation. Liver cancer development recapitulates, in part, fetal liver development in terms of the emergence of cells expressing certain stem cell markers and the activation of signaling pathways during liver development and inflammation/regeneration (Table 1).

Normal liver development program. Hepatic genes are first induced in a segment of ventral endoderm, requiring FGF signaling from the adjacent cardiogenic mesoderm and BMP signaling from the septum transversum (45, 46). Recent analysis of zebrafish indicates the involvement of Wnt2b from the lateral plate mesoderm in liver specification (47). Another recent study using conditional adenomatosis polyposis coli (Apc) knockout mice under the α-fetoprotein (Afp) promoter further indicated that activation of Wnt signaling allows the induction of hepatic specification and inhibition of hepatic maturation (48). Once the hepatic endoderm is specified and the liver bud begins to grow, the cells become hepatoblasts with the ability to differentiate into hepatic and biliary lineages. These cells have the self-renewal and asymmetric division features of stem cells and can repopulate normal and injured liver. Various growth factors influence hepatoblast differentiation into hepatocytes and cholangiocytes, including Wnt signaling, HGF signaling, oncostatin M (OSM) signaling, and Jagged 1/Notch (JAG1/Notch) signaling (49–51).

Signaling pathways activated in liver cancer. Signaling pathways activated in normal liver development are also activated in CLDs and may mediate the development and maintenance of liver CSCs (Table 2) (see also a recent review article highlighting the role of signaling pathways on self-renewal and differentiation of liver CSCs; ref. 52). For example, signaling of FGF and Wnt is implicated in HCC development (53–55), and Wnt signaling regulates hepatoblasts and liver CSC self-renewal (18, 56–60). Recent application of massive parallel sequencing technologies have confirmed previous findings that somatic mutations of genes in the Wnt/β-catenin signaling pathways, such as axin and β-catenin, are common HCC events (61–63). Wnt and TGF-β signaling pathways may collaborate in the development of HCC or HCC-CCA with poor prognosis (64, 65). Signaling of OSM and BMP4 appears to induce hepatocytic differentiation of liver CSCs (66, 67), while TGF-β signaling is implicated in the biliary differentiation of hepatoblasts; loss of TGF-β signaling by β2-spectrin knockout resulted in the expansion of progenitor cells in mice (68, 69). TGF-β signaling may also regulate the development and maintenance of HCC and liver CSCs, but its role seems paradoxical and is often referred to as a double-edged sword (70–73). In addition, TGF-β signaling may promote HCC progression by recruiting regulatory T cells to establish a favorable microenvironment for tumor metastasis (74, 75).

IL-6/STAT3 signaling is involved in liver inflammation/regeneration and may regulate the population of liver CSCs in collaboration with TGF-β signaling (70, 76, 77). JAG1/Notch signaling induces biliary differentiation of hepatoblasts, but its role in HCC remains controversial (78, 79). Signaling through HGF and its receptor c-Met has a pleiotropic role in regulating hepatic progenitors to hepatocytic/biliary differentiation (80, 81) and is implicated in the maintenance of liver CSCs through epithelial-mesenchymal transition (82).

Stem cell markers detected in hepatic stem/progenitor cells and liver CSCs. Hepatoblasts express biliary markers such as cytokeratin 19 (CK19) and EpCAM as well as hepatocyte markers such as albumin and AFP (27, 83). Hepatoblasts also express a variety of markers potentially detected in ectodermal or mesodermal lineages (84–92). Similar to the signaling pathways activated in both normal liver and cancer development, hepatoblasts/hepatic progenitor cells, and liver CSCs share a number of oncofetal markers (Tables 1 and 2 and refs. 17, 18, 20, 21, 27, 58, 83, 93–98). Interestingly, recent studies showed that some of these liver CSC markers are also functionally involved in the maintenance of

---

**Table 1**

<table>
<thead>
<tr>
<th>Signaling pathway</th>
<th>Role in normal liver development (species)</th>
<th>Role in liver cancer development (source)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMP</td>
<td>Liver specification from endoderm (mouse)</td>
<td>Differentiation of CD133+ CSC (PLC/PRL/5, Huh7, MHCC-97L)</td>
<td>46, 66</td>
</tr>
<tr>
<td>FGF</td>
<td>Liver specification from endoderm (mouse)</td>
<td>Cell proliferation and angiogenesis (HCC-1.2, HepG2, Hep3B)</td>
<td>45, 53, 54</td>
</tr>
<tr>
<td>Wnt</td>
<td>Liver specification from endoderm (zebrafish, mouse), inhibition of hepatic maturation (mouse), biliary differentiation of hepatoblast (mouse)</td>
<td>Liver CSC self-renewal (Huh1, Huh7, SMMC7721), cell proliferation (Hep3B)</td>
<td>18, 47, 48, 51, 54, 58, 59</td>
</tr>
<tr>
<td>OSM</td>
<td>Hepatocytic differentiation of hepatoblast (mouse)</td>
<td>Differentiation of EpCAM+ CSC (Huh1, Huh7, primary HCC)</td>
<td>49, 67</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Biliary differentiation of hepatoblast (mouse)</td>
<td>Controversial (mouse, rat, Huh7, primary HCC)</td>
<td>64, 65, 68–73</td>
</tr>
<tr>
<td>JAG1/Notch</td>
<td>Biliary differentiation of hepatoblast (mouse)</td>
<td>Controversial (mouse, primary HCC)</td>
<td>50, 78, 79</td>
</tr>
<tr>
<td>IL-6/STAT3</td>
<td>Liver regeneration (mouse)</td>
<td>Liver CSC maintenance (mouse)</td>
<td>70, 76, 77</td>
</tr>
<tr>
<td>HGF/c-Met</td>
<td>Liver regeneration (mouse), hepatocyte transdifferentiation into biliary epithelium (rat)</td>
<td>Epithelial-mesenchymal transition (mouse)</td>
<td>49, 50, 80–82</td>
</tr>
</tbody>
</table>
CSC features. For example, EpCAM enhances Wnt signaling in ES cells and cancer (99, 100), and CD133 expression is required for the maintenance of CD133+ liver CSCs through neurotensin/IL-8/CXCL1 signaling activation (101). In addition, a CD44 variant regulates the redox status by stabilizing xCT and protecting CSCs from oxidative stress (102), while CD13 reduces cell damage induced by oxidative stress after exposure to genotoxic reagents (19). Thus, the functional involvement of most liver CSC markers in the maintenance of liver CSC features potentially makes them a good target for the eradication of liver CSCs.

**Clinical application of the concept of liver CSCs**

According to the CSC concept, heterogeneous populations of liver cancer cells are dictated and maintained at least partially by liver CSCs. Therefore, identification of signaling pathways as well as stem cell markers activated in liver CSCs will profoundly affect the development of novel liver cancer diagnosis and treatment strategies.

**Diagnosis and prognostic stratification**

Survival of liver cancer patients after radical resection varies on an individual basis, even with early diagnosis. Conventional histologic diagnosis of tumor samples cannot predict the prognosis of liver cancer patients who receive radical treatment. To overcome these limitations, gene expression profiling technologies have been applied (117, 118). Currently, the finding of a stem cell–like gene expression signature is of great interest because it reflects the malignant nature of a tumor with poor survival outcome (Figure 2 and refs. 18, 109, 119, 120). Gene expression profiles generally reflect the characteristics of the dominant cell population, so a poor prognosis of HCC in patients with stemness-associated gene expression traits is assumed to reflect the abundance of liver CSCs with highly tumorigenic and/or metastatic features.

Accordingly, recent evidence has suggested that the presence of liver CSCs in resected specimens could be associated with poor prognosis of HCC patients after radical resection (121, 122). However, predictive values of single liver CSC markers remain controversial and need validation in independent cohorts (52). Rather, a combination of several CSC markers may provide greater specificity and reliability in predicting HCC prognosis (57, 123). Stemness has also recently been identified as a predictive marker of ICC prognosis (124). CSCs have a highly invasive and metastatic capacity and can be isolated from peripheral blood mononuclear cells as circulating tumor cells, and thus may provide diagnostic or prognostic information (125–127).

**Treatment resistance and CSC-targeted therapy**

The discovery of liver CSCs has also elucidated detailed mechanisms of treatment failure in liver cancer. Poor prognosis after radical resection of EpCAM+AFP+...
HCCs can be explained by the high frequency of portal vein invasion, which may result in the early recurrence of HCC due to microdissemination in the residual liver (18, 57). Although EpCAM+ CSCs showed chemoresistance against genotoxic reagent 5-fluorouracil (5-FU), these cells exhibited Wnt signaling activation and sensitivity to Wnt signaling inhibitor (56). CD90+ liver CSCs co-expressing CD44 were detected in all HCC tissues from 13 HCC patients who underwent surgery (20). These cells lost their highly tumorigenic capacity in a xenotransplantation model when anti-CD44-neutralizing antibodies were systematically administrated (20).

Transcatheter arterial chemoembolization (TACE) is used to treat HCC patients at intermediate stages, and CD13+ liver CSCs survived together with the fibrous capsule after TACE, which may result in local recurrence (19). Such CD13+ CSCs were eradicated by application of a CD13 inhibitor in combination with 5-FU in a mouse xenograft model (19). Among HBV-related HCC patients who received surgery, CD133+ liver CSCs appeared in advanced stages and correlated with early recurrence and poor prognosis (128).

In advanced stages, genotoxic agents such as 5-FU or doxorubicin showed limited antitumor activities against HCC, and sorafenib tosylate only modestly prolonged overall survival (129). These CD133+ liver CSCs showed activation of the Akt/PKB survival pathway and chemoresistance to doxorubicin or 5-FU, while an AKT1 inhibitor suppressed survival signaling of CD133+ liver CSCs (130). Lupeol, a phytochemical in fruit and vegetables, also inhibits the self-renewal of CD133+ liver CSCs through inhibition of the PTEN/Akt/ABCG2 signaling pathway (131). The discovery and exploration of liver CSCs has expanded our knowledge of the mechanisms by which liver cancers obtain tumorigenic, metastatic, and chemoresistance capacities. The development of new diagnostic and treatment strategies targeting liver CSCs to improve the survival of liver cancer patients is currently underway.

Future challenges

The liver CSC concept has been acknowledged to explain the molecular diversity of malignant phenotypes in liver cancer. However, many questions remain, including the role of hepatitis viruses, the origin of liver CSCs, the existence and role of the stem cell niche, similarities and differences between normal hepatic stem/progenitor cells and liver CSCs, the timing of CSC emergence, CSC concept universality in liver cancers, and the relationship between CSC plasticity and clonal evolution accompanied by genetic and epigenetic changes (11).

Although chronic HBV and HCV infections are two major risk factors for the development of liver cancer, their roles in liver CSCs are largely unknown. It is also unclear whether HBV and HCV infect and replicate in hepatic stem/progenitor cells, but a recent study suggested that HCV could replicate in human fetal hepatocytes (132). Clinicopathological analysis of surgically resected HCC specimens suggested that EpCAM+ CSCs were more frequently detected in HBV+ HCCs than in HCV-related HCCs, although a validation study using a large independent cohort is required (18). A recent study supported the role of HBx in the activation of HepG2 cell EpCAM expression accompanied by enhanced cell migration and sphere formation (133). Continued expression of HCV using a subgenomic replicon system was shown to induce stem cell–like properties, including the activation of CD133, AFP, CK19, and c-Myc (134). Moreover, TLR4 was induced in HCV NS5A transgenic mice following alcohol exposure, and the resulting HCC showed activation of stem cell signatures including CD133 and Nanog (106). As liver CSCs are considered resistant to cellular stresses, it should be clarified whether HBV or HCV infection directly induces stemness through interaction with signaling pathways, or whether the results reflect enrichment of stress-resistant CSCs in certain conditions.

The target cell population of malignant transformation is generally controversial in human cancer, but accumulating evidence suggests that cancer heterogeneity may derive from different cells of origin as well as diverse genetic mutations (135). Recent studies have indicated the spontaneous conversion of non-stem cells to stem-like cells in normal breast epithelial cells and suggested that the biological state of normal cells of origin before transformation may be a determinant of the behavior of their descendants following transformation (136). Similarly, a recent study suggested the unexpected plasticity of normal mature hepatocytes to dedifferentiate into progenitor cells in rodent...
review series


26. Roskams T. Liver stem cells and their implication in hepatic and cholangiocarcinoma. *Onco-
genome*. 2006;23(7–8):3818–3822.
38. Bono R, et al. Transforming the microen
41. Morris SM, Baek JY, Koszarek A, Kanneganti S, Kno
blaugh SE, Grady WM. Transforming growth fac
44. Whitaker S, Marrais R, Zhui AX. The role of sig
gnaling pathways in the development and treat-
47. Thenappan A, et al. Role of transforming growth fac
48. Mishra L, et al. Liver stem cells sensitive to 5-Fluorouracil by induc-
50. Thenappan A, et al. Role of transforming growth factor-
51. Morrisey EE, et al. Liver stem cells sensitive to 5-Fluorouracil by induc-
53. Budih A, Wang XW. Transforming the microen
57. Villanueva A, et al. Notch signaling inhibits hepa-
59. Ishikawa T, et al. Hepatocyte growth factor/c-met sig-
naling is required for biliary differentiation of progeni
61. Ding W, et al. Epithelial-to-mesenchymal transi
63. Nishimura H, et al. Liver stem cells sensitive to 5-Fluorouracil by induc-
64. Roskams T, Cassiman D, De Vos R, Libbrecht L. Neuroregulation of the neuroendocrine compart-
65. Crosby HA, Kelly DA, Strain AJ. Human hepatic stem-like cells isolated using c-kit or CD34 can differ-
106. Qiou Q, Hernandez JC, Dean AM, Rao PH, Dar - }
110. Hong H, et al. Suppression of induced pluripo - }